TCGA-XF-A9SU-01A-31R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.978975033
- os_event
- true
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG589 | — | — | 0.845 |
| 2 | TCGA-AN-A0FT-01A-11R-A034-07 | — | B | 0.830 |
| 3 | 09f758e5-6be1-4f29-ac92-869d92f8fbcf | — | — | 0.789 |
| 4 | 773b41d4-8c43-4777-99b8-190c7e7793e0 | — | — | 0.781 |
| 5 | TCGA-60-2720-01A-01R-0851-07 | — | cohortSQ1 | 0.781 |
| 6 | TCGA-85-A4JC-01A-11R-A24Z-07 | — | cohortSQ1 | 0.761 |
| 7 | b9189c77-004e-461a-9c15-b504b12a3030 | — | — | 0.751 |
| 8 | MDT-AP-2372 | Med | Medulloblastoma | 0.749 |
| 9 | SAMN03290888 | — | — | 0.748 |
| 10 | 9a4f9e4a-dc97-4f8d-9075-537b62fb98d3 | — | — | 0.743 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |